Diagnosis and management of pancreatic neuroendocrine tumor in von hippel-lindau disease

Kenji Tamura, Isao Nishimori, Tetsuhide Ito, Ichiro Yamasaki, Hisato Igarashi, Taro Shuin

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The pancreatic manifestations seen in patients with von Hippel-Lindau (VHL) disease are subdivided into 2 categories: pancreatic neuroendocrine tumors (NET), and cystic lesions, including simple cyst and serous cystadenoma. The VHL-associated cystic lesions are generally asymptomatic and do not require any treatment, unless they are indistinguishable from other cystic tumor types with malignant potential. Because pancreatic NET in VHL disease are non-functioning and have malignant potential, it is of clinical importance to find and diagnose these as early as possible. It will be recommended that comprehensive surveillance using dynamic computed tomography for abdominal manifestations, including pancreatic NET, should start from the age of 15 years in VHL patients. Unlike sporadic non-functioning NET without VHL disease, in which surgical resection is generally recommended, VHL patients at lower metastatic risk of pancreatic NET should be spared the risks of operative resection.

Original languageEnglish
Pages (from-to)4515-4518
Number of pages4
JournalWorld Journal of Gastroenterology
Volume16
Issue number36
DOIs
Publication statusPublished - Sep 28 2010

Fingerprint

von Hippel-Lindau Disease
Neuroendocrine Tumors
Serous Cystadenoma
Cysts
Tomography
Neoplasms

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Diagnosis and management of pancreatic neuroendocrine tumor in von hippel-lindau disease. / Tamura, Kenji; Nishimori, Isao; Ito, Tetsuhide; Yamasaki, Ichiro; Igarashi, Hisato; Shuin, Taro.

In: World Journal of Gastroenterology, Vol. 16, No. 36, 28.09.2010, p. 4515-4518.

Research output: Contribution to journalArticle

Tamura, K, Nishimori, I, Ito, T, Yamasaki, I, Igarashi, H & Shuin, T 2010, 'Diagnosis and management of pancreatic neuroendocrine tumor in von hippel-lindau disease', World Journal of Gastroenterology, vol. 16, no. 36, pp. 4515-4518. https://doi.org/10.3748/wjg.v16.i36.4515
Tamura, Kenji ; Nishimori, Isao ; Ito, Tetsuhide ; Yamasaki, Ichiro ; Igarashi, Hisato ; Shuin, Taro. / Diagnosis and management of pancreatic neuroendocrine tumor in von hippel-lindau disease. In: World Journal of Gastroenterology. 2010 ; Vol. 16, No. 36. pp. 4515-4518.
@article{1365c64cd1c84658a729a80f35140f85,
title = "Diagnosis and management of pancreatic neuroendocrine tumor in von hippel-lindau disease",
abstract = "The pancreatic manifestations seen in patients with von Hippel-Lindau (VHL) disease are subdivided into 2 categories: pancreatic neuroendocrine tumors (NET), and cystic lesions, including simple cyst and serous cystadenoma. The VHL-associated cystic lesions are generally asymptomatic and do not require any treatment, unless they are indistinguishable from other cystic tumor types with malignant potential. Because pancreatic NET in VHL disease are non-functioning and have malignant potential, it is of clinical importance to find and diagnose these as early as possible. It will be recommended that comprehensive surveillance using dynamic computed tomography for abdominal manifestations, including pancreatic NET, should start from the age of 15 years in VHL patients. Unlike sporadic non-functioning NET without VHL disease, in which surgical resection is generally recommended, VHL patients at lower metastatic risk of pancreatic NET should be spared the risks of operative resection.",
author = "Kenji Tamura and Isao Nishimori and Tetsuhide Ito and Ichiro Yamasaki and Hisato Igarashi and Taro Shuin",
year = "2010",
month = "9",
day = "28",
doi = "10.3748/wjg.v16.i36.4515",
language = "English",
volume = "16",
pages = "4515--4518",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "36",

}

TY - JOUR

T1 - Diagnosis and management of pancreatic neuroendocrine tumor in von hippel-lindau disease

AU - Tamura, Kenji

AU - Nishimori, Isao

AU - Ito, Tetsuhide

AU - Yamasaki, Ichiro

AU - Igarashi, Hisato

AU - Shuin, Taro

PY - 2010/9/28

Y1 - 2010/9/28

N2 - The pancreatic manifestations seen in patients with von Hippel-Lindau (VHL) disease are subdivided into 2 categories: pancreatic neuroendocrine tumors (NET), and cystic lesions, including simple cyst and serous cystadenoma. The VHL-associated cystic lesions are generally asymptomatic and do not require any treatment, unless they are indistinguishable from other cystic tumor types with malignant potential. Because pancreatic NET in VHL disease are non-functioning and have malignant potential, it is of clinical importance to find and diagnose these as early as possible. It will be recommended that comprehensive surveillance using dynamic computed tomography for abdominal manifestations, including pancreatic NET, should start from the age of 15 years in VHL patients. Unlike sporadic non-functioning NET without VHL disease, in which surgical resection is generally recommended, VHL patients at lower metastatic risk of pancreatic NET should be spared the risks of operative resection.

AB - The pancreatic manifestations seen in patients with von Hippel-Lindau (VHL) disease are subdivided into 2 categories: pancreatic neuroendocrine tumors (NET), and cystic lesions, including simple cyst and serous cystadenoma. The VHL-associated cystic lesions are generally asymptomatic and do not require any treatment, unless they are indistinguishable from other cystic tumor types with malignant potential. Because pancreatic NET in VHL disease are non-functioning and have malignant potential, it is of clinical importance to find and diagnose these as early as possible. It will be recommended that comprehensive surveillance using dynamic computed tomography for abdominal manifestations, including pancreatic NET, should start from the age of 15 years in VHL patients. Unlike sporadic non-functioning NET without VHL disease, in which surgical resection is generally recommended, VHL patients at lower metastatic risk of pancreatic NET should be spared the risks of operative resection.

UR - http://www.scopus.com/inward/record.url?scp=77957600534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957600534&partnerID=8YFLogxK

U2 - 10.3748/wjg.v16.i36.4515

DO - 10.3748/wjg.v16.i36.4515

M3 - Article

C2 - 20857520

AN - SCOPUS:77957600534

VL - 16

SP - 4515

EP - 4518

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 36

ER -